在HFpEF中的动脉硬:从临床洞察到床边行动
Param Darpan Sheth1, Chandana Srinath
1From the Department of General Medicine, J.S.S. Medical College, JSS Academy of Higher Education and Research, Mysuru, India.
Cardiology in review
|September 8, 2025
概括
动脉硬度评估为诊断心力衰竭与保留射出分数 (HFpEF) 提供了关键的见解. 测量脉冲波速度和其他标记器有助于早期检测和风险分层.
科学领域:
- 心脏病学 心脏病学
- 血管生理学 血管生理学
- 医学诊断 医学诊断 医学诊断
背景情况:
- 心脏衰竭与保存的喷射分数 (HFpEF) 是常见的和上升,经常呈现不清楚的症状.
- 心声图在诊断HFpEF时可能没有确定性,导致诊断延迟.
- 动脉硬性越来越被认为是HFpEF发展的重要因素.
研究的目的:
- 探索动脉硬性在HFpEF病理生理学中的作用.
- 评估动脉硬度测量作为HFpEF中的诊断和预后工具.
- 突出动脉硬的潜力作为可修改的治疗目标.
主要方法:
- 使用脉冲波速度,增强指数和心血管指数量化动脉硬度.
- 动脉硬度标志物与透静功能,临床结果和住院病例的相关性.
- 在患有模两可的心声回声学发现的患者中评估动脉硬性.
主要成果:
- 升高的动脉硬与心室放松受损和不良的心脏重塑有关.
- 增加的脉冲波速度和心血管指数与更差的透静功能,更高的住院率和死亡率相关.
- 动脉硬度评估在模两可的HFpEF病例中提供了诊断的清晰度.
结论:
- 动脉硬度是诊断和管理HFpEF的一个有价值的,未被充分利用的参数.
- 测量动脉硬度可以改善早期检测,风险分层和个性化治疗.
- 通过改变生活方式和药物来准动脉硬可能会改善患者的治疗结果.
相关概念视频
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
365
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
365
Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Peripheral Artery Disease III: Interprofessional Care
252
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
252
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Peripheral Artery Disease I: Introduction
320
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
320
Heart Failure VI: Adjunct Therapies
263
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
263


